Fundraising FoxBioheng
4 known investors
Find your way into Bioheng
Sign up to see every warm intro you have to Bioheng
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bioheng team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Imviva is a clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases. The company focuses on creating safer, more effective off-the-shelf cell therapies designed to improve patient access and outcomes in regenerative medicine.
Founders & leadership
Investors · 4
How we know: the company's own site · Decheng Capital's portfolio page · funding news · biocentury.com · the VCSheet dataset · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
Funding
SEC filings, press & company announcements$14.8M disclosed across 1 round · 2019
- $14.8MSeries AFeb 2019 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Bioheng do?
- Imviva is a clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases. The company focuses on creating safer, more effective off-the-shelf cell therapies designed to improve patient access and outcomes in regenerative medicine.
- Who are Bioheng's investors?
- Bioheng's investors include Decheng Capital, GL Ventures, Hillhouse Capital, Shenzhen Capital Group.
- How much funding has Bioheng raised?
- Bioheng has disclosed $14.8M raised across 1 round.